Does dapagliflozin provide similar advantages to empagliflozin in reducing cardiorenal risk and safety in Indonesian patients with T2DM?
Dapagliflozin and empagliflozin demonstrate comparable effectiveness and safety for cardiorenal risk reduction at 12 months in a real-world T2DM population.
Dapagliflozin and Empagliflozin provide similar advantages in reducing cardiorenal risk and safety after 12 months of treatment in Indonesian patients with T2DM.
Cokro et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: